These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 26834162)

  • 21. Fidaxomicin inhibits spore production in Clostridium difficile.
    Babakhani F; Bouillaut L; Gomez A; Sears P; Nguyen L; Sonenshein AL
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S162-9. PubMed ID: 22752866
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fidaxomicin for treatment of clostridium difficile-associated diarrhea and its potential role for prophylaxis.
    Hostler CJ; Chen LF
    Expert Opin Pharmacother; 2013 Aug; 14(11):1529-36. PubMed ID: 23683070
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment) in Spain.
    Rubio-Terrés C; Cobo Reinoso J; Grau Cerrato S; Mensa Pueyo J; Salavert Lletí M; Toledo A; Anguita P; Rubio-Rodríguez D; Watt M; Gani R
    Eur J Clin Microbiol Infect Dis; 2015 Nov; 34(11):2213-23. PubMed ID: 26407619
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin?
    Cornely OA
    Clin Microbiol Infect; 2012 Dec; 18 Suppl 6():28-35. PubMed ID: 23121552
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI.
    Sattar A; Thommes P; Payne L; Warn P; Vickers RJ
    J Antimicrob Chemother; 2015; 70(6):1757-62. PubMed ID: 25652749
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanism of action of and mechanism of reduced susceptibility to the novel anti-Clostridium difficile compound LFF571.
    Leeds JA; Sachdeva M; Mullin S; Dzink-Fox J; Lamarche MJ
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4463-5. PubMed ID: 22644023
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fidaxomicin versus vancomycin for Clostridium difficile infection.
    Louie TJ; Miller MA; Mullane KM; Weiss K; Lentnek A; Golan Y; Gorbach S; Sears P; Shue YK;
    N Engl J Med; 2011 Feb; 364(5):422-31. PubMed ID: 21288078
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of fidaxomicin for the treatment of Clostridium difficile infection.
    Juang P; Hardesty JS
    J Pharm Pract; 2013 Oct; 26(5):491-7. PubMed ID: 24064437
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of Clostridium difficile infections.
    Soriano MM; Johnson S
    Infect Dis Clin North Am; 2015 Mar; 29(1):93-108. PubMed ID: 25573676
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Antimicrobial profile and clinical evidence of fidaxomicin (Dafclir
    Takeda S; Miki T
    Nihon Yakurigaku Zasshi; 2019; 154(4):217-229. PubMed ID: 31597902
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fidaxomicin: a minimally absorbed macrocyclic antibiotic for the treatment of Clostridium difficile infections.
    Soriano MM; Liao S; Danziger LH
    Expert Rev Anti Infect Ther; 2013 Aug; 11(8):767-76. PubMed ID: 23977933
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fecal pharmacokinetics/pharmacodynamics characteristics of fidaxomicin and vancomycin against Clostridioides difficile infection elucidated by in vivo feces-based infectious evaluation models.
    Tashiro S; Taguchi K; Enoki Y; Matsumoto K
    Clin Microbiol Infect; 2023 May; 29(5):616-622. PubMed ID: 36574949
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fidaxomicin: first-in-class macrocyclic antibiotic.
    Mullane KM; Gorbach S
    Expert Rev Anti Infect Ther; 2011 Jul; 9(7):767-77. PubMed ID: 21810048
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Investigation of the MICs of fidaxomicin and other antibiotics against Hungarian Clostridium difficile isolates.
    Eitel Z; Terhes G; Sóki J; Nagy E; Urbán E
    Anaerobe; 2015 Feb; 31():47-9. PubMed ID: 25139122
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fidaxomicin for treatment of Clostridium difficile infection in clinical practice: a prospective cohort study in a French University Hospital.
    Pichenot M; Héquette-Ruz R; Le Guern R; Grandbastien B; Charlet C; Wallet F; Schiettecatte S; Loeuillet F; Guery B; Galperine T
    Infection; 2017 Aug; 45(4):425-431. PubMed ID: 28120176
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fidaxomicin: a macrocyclic antibiotic for the treatment of Clostridium difficile infection.
    Hardesty JS; Juang P
    Pharmacotherapy; 2011 Sep; 31(9):877-86. PubMed ID: 21923589
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnosis and management of Clostridium difficile infection.
    Dupont HL
    Clin Gastroenterol Hepatol; 2013 Oct; 11(10):1216-23; quiz e73. PubMed ID: 23542332
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fidaxomicin: a macrocyclic antibiotic for the management of Clostridium difficile infection.
    Sullivan KM; Spooner LM
    Ann Pharmacother; 2010 Feb; 44(2):352-9. PubMed ID: 20071495
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro activity of surotomycin against contemporary clinical isolates of toxigenic Clostridium difficile strains obtained in Spain.
    Reigadas E; Alcalá L; Marín M; Pelaéz T; Martin A; Iglesias C; Bouza E
    J Antimicrob Chemother; 2015 Aug; 70(8):2311-5. PubMed ID: 25876881
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Surveillance for antimicrobial resistance in Australian isolates of Clostridium difficile, 2013-14.
    Knight DR; Giglio S; Huntington PG; Korman TM; Kotsanas D; Moore CV; Paterson DL; Prendergast L; Huber CA; Robson J; Waring L; Wehrhahn MC; Weldhagen GF; Wilson RM; Riley TV
    J Antimicrob Chemother; 2015 Nov; 70(11):2992-9. PubMed ID: 26221017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.